How should a patient with paroxysmal nocturnal hemoglobinuria be managed, including complement inhibition therapy, vaccination, supportive care, anticoagulation, and monitoring?

Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Patients with PNH should receive complement inhibitor therapy as first-line treatment, with C5 inhibitors (eculizumab or ravulizumab) being the established standard, though proximal complement inhibitors (targeting C3, factor B, or factor D) offer superior control of both intravascular and extravascular hemolysis for patients who remain anemic or transfusion-dependent despite C5 inhibition. 1, 2

Complement Inhibition Therapy

C5 Inhibitors (First-Line)

• Eculizumab or ravulizumab are the established first-line complement inhibitors that block terminal complement activation, reducing intravascular hemolysis, improving hemoglobin levels, decreasing transfusion requirements, reducing thrombotic risk, and improving overall survival 1, 2
• Ravulizumab offers the advantage of longer dosing intervals compared to eculizumab, reducing treatment burden 1
• Approximately 50% of patients on C5 inhibitors still require blood transfusions due to C3-mediated extravascular hemolysis (EVH), which these agents do not prevent 1, 3

Proximal Complement Inhibitors (For Inadequate C5 Response)

• Pegcetacoplan (anti-C3), iptacopan (factor B inhibitor), and factor D inhibitors should be used in patients who remain anemic or transfusion-dependent despite C5 inhibition 1, 3
• These agents control both intravascular hemolysis and reduce C3 fragment deposition, thereby preventing extravascular hemolysis 1, 3
• Iptacopan is administered orally at 200 mg twice daily, offering convenience over intravenous therapies 4
• Caution: Proximal inhibitors may increase the risk of breakthrough hemolysis due to complement cascade effects and accumulation of PNH red blood cells 3

Vaccination (Critical and Mandatory)

Meningococcal Vaccination

• All patients must receive meningococcal vaccination at least 2 weeks before initiating complement inhibitor therapy unless the risk of delaying treatment outweighs infection risk 5, 6
• Administer quadrivalent meningococcal A, C, W, Y conjugate vaccine 6, 7
• Administer meningococcal serogroup B vaccine (Bexsero or Trumenba) 8
• Re-vaccination every 3 years is essential during chronic complement inhibitor therapy, or based on serologic response monitoring 7
• Serologic protection is defined as serum bactericidal assay (rSBA) titer ≥1:8 7
• Response rates vary by serogroup: A (78%), C (87%), W (48%), Y (70%) 7

Antibiotic Prophylaxis

• Ciprofloxacin prophylaxis should be initiated when starting complement inhibitors to reduce meningococcal infection risk 8
• Standby ciprofloxacin therapy and immediate medical evaluation are recommended if meningococcal infection is suspected 7

Supportive Care

Transfusion Support

• Blood transfusions are indicated for symptomatic anemia or hemoglobin levels causing significant functional impairment 2
• Extended antigen-matched red cells (C/c, E/e, K, Jk^a^/Jk^b^, Fy^a^/Fy^b^, S/s) should be used to minimize alloimmunization risk 8

Iron Supplementation

• Erythropoietin with or without intravenous iron should be initiated in all patients experiencing hemolysis to support erythropoiesis 8
• Monitor serum ferritin levels to assess iron status 9

Anticoagulation

Thrombosis Prevention

• Anticoagulation prophylaxis is critical given the high thrombotic risk in PNH, which historically accounts for significant mortality 1, 2
• Complement inhibitors significantly reduce thrombotic events, but anticoagulation decisions must be individualized based on thrombotic history and bleeding risk 1
• For patients with documented thrombosis, therapeutic anticoagulation should be continued long-term 10
• Non-heparin anticoagulants (direct oral anticoagulants, fondaparinux) are preferred if heparin-induced thrombocytopenia is a concern 11

Monitoring

Laboratory Monitoring

• Flow cytometry on peripheral blood is the gold standard for diagnosis and monitoring PNH clone size 2, 12
• Monitor hemoglobin, hematocrit, reticulocyte count, lactate dehydrogenase (LDH), and bilirubin to assess hemolysis 8, 12
• Assess for breakthrough hemolysis during complement inhibitor therapy by monitoring LDH elevation, hemoglobin decline, and symptoms 12, 4
• Monitor complement hemolytic activity (C3, C4, CH50, AP50) if extending dosing intervals of C5 inhibitors 6

Clinical Monitoring

• Assess for symptoms of hemolysis: fatigue, dyspnea, dark urine (particularly morning urine), chest pain, and smooth muscle dystonia 1, 13
• Monitor for thrombotic complications including cerebral venous sinus thrombosis, portal/splanchnic vein thrombosis, and pulmonary embolism 2, 13
• Evaluate for bone marrow failure manifestations: cytopenias and transfusion requirements 2, 13

Frequency of Monitoring

• Monthly hospital visits are common (56.7% of patients require ≥1 visit per month), with 46.7% needing time off work or school 14
• More frequent monitoring is required during breakthrough hemolysis episodes or when switching therapies 4

Special Considerations

Pregnancy

• Women who develop PNH triggered by pregnancy benefit from C5 inhibitors, which should be administered for at least 6 months and discontinued only after a minimum of 3 months of stabilized renal function 6

Hematopoietic Stem Cell Transplantation

• Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is indicated for PNH patients with severe aplastic anemia (SAA/PNH) who failed immunosuppressive therapy 15
• Allo-HSCT remains the only curative option for PNH 13

Breakthrough Hemolysis Management

• Infectious triggers (such as enteritis) can precipitate breakthrough hemolysis despite complement inhibition 4
• Switching from C5 inhibitors to proximal complement inhibitors (e.g., iptacopan) can rapidly improve anemia and symptoms within 1-2 weeks 4